SCHEMBL4157916

SCHEMBL4157916

COc1ccc(N)cc1C=C1c2ccccc2CCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.45
ALDH1A1 P00352 7/20 0.45
SMN1; SMN2 Q16637 6/20 0.45
LMNA P02545 5/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
CASP3 P42574 2/20 0.45
SENP8 Q96LD8 2/20 0.45
SENP7 Q9BQF6 2/20 0.45
SENP6 Q9GZR1 2/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 2/20 0.44
PLA2G1B P04054 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
SMPD1 P17405 1/20 0.43
POLB P06746 1/20 0.43
MIF P14174 1/20 0.43
HTT P42858 2/20 0.42
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4158016 0.84 MAPT (0.53) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL4159194 0.83 MAPT (0.45) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL4164482 0.82 MAPT (0.56) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL4040966 0.78 MAPT (0.54) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL4173996 0.76 NR3C1 (0.62) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL4163664 0.76 MAPT (0.68) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4155408 0.75 MAPT (0.69) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL14721584 0.74 MAPT (0.48) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL4163391 0.74 ALDH1A1 (0.55) MAPTALDH1A1SMN1; SMN2LMNARAB9A
SCHEMBL14721583 0.74 MAPT (0.48) MAPTALDH1A1SMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 MAPT 3591/4885ALDH1A1 1812/4885SMN1; SMN2 4708/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 MAPT 3416/4885ALDH1A1 1728/4885SMN1; SMN2 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.